Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347463 | 0.87 | CYP1A2 (0.66) | ADORA2AADORA3ADORA2BADORA1CYP1A2 | |
| SCHEMBL3967723 | 0.85 | ADORA3 (0.59) | ADORA2AADORA3ADORA2BADORA1SLC29A1 | |
| SCHEMBL217116 | 0.85 | CYP2C19 (0.60) | ADORA2AADORA3ADORA2BADORA1CYP2C19 | |
| SCHEMBL9545416 | 0.84 | CYP1A2 (0.55) | ADORA3ADORA1CYP1A2 | |
| SCHEMBL5999287 | 0.84 | CYP1A2 (0.55) | ADORA2AADORA3ADORA2BADORA1CYP1A2 | |
| SCHEMBL7915387 | 0.84 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BADORA1CYP1A2 | |
| SCHEMBL1611240 | 0.83 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BADORA1CYP2C19 | |
| SCHEMBL4813930 | 0.83 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BADORA1CYP2C19 | |
| SCHEMBL2208478 | 0.82 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL27690308 | 0.82 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | NUDT1, PNP, HPRT1 | ADORA2A 112/4885ADORA3 132/4885ADORA2B 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.